Evidence map›Paper›PMID 38047086›Full record

ArticleiScience2023

Functional and spatial proteomics profiling reveals intra- and intercellular signaling crosstalk in colorectal cancer.

Christina Plattner, Giorgia Lamberti, Peter Blattmann, Alexander Kirchmair, Dietmar Rieder, Zuzana Loncova, Gregor Sturm, Stefan Scheidl, Marieke Ijsselsteijn, Georgios Fotakis and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Spatial proteomics: technical evolution and applications in cancer research.Frontiers in cell and developmental biology · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Impact ofFrontiers in immunology · 2025
    Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Christina PlattnerBiocenter, Institute of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Giorgia LambertiBiocenter, Institute of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Peter BlattmannDepartment of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8092 Zurich, Switzerland.
Alexander KirchmairBiocenter, Institute of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Dietmar RiederBiocenter, Institute of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Zuzana LoncovaBiocenter, Institute of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Gregor SturmBiocenter, Institute of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Stefan ScheidlDepartment of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Marieke IjsselsteijnDepartment of Pathology, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands.
Georgios FotakisBiocenter, Institute of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Asma NoureenBiocenter, Institute of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Rebecca LisandrelliBiocenter, Institute of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Nina BöckBiocenter, Institute of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Niloofar NematiBiocenter, Institute of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Anne KrogsdamBiocenter, Institute of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Sophia DaumBiocenter, Institute of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Francesca FinotelloBiocenter, Institute of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Antonios SomarakisDepartment of Radiology, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands.
Alexander SchäferDepartment of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8092 Zurich, Switzerland.
Doris WilflingsederInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Miguel Gonzalez AceraDepartment of Medicine 1, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
Dietmar ÖfnerDepartment of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Lukas A HuberBiocenter, Institute of Cell Biology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Hans CleversHubrecht Institute, 3584 CT Utrecht, the Netherlands.
Christoph BeckerDepartment of Medicine 1, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
Henner F FarinInstitute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596 Frankfurt am Main, Germany.
Florian R GretenInstitute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, 60596 Frankfurt am Main, Germany.
Ruedi AebersoldDepartment of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8092 Zurich, Switzerland.
Noel F C C de MirandaDepartment of Pathology, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands.
Zlatko TrajanoskiBiocenter, Institute of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.

Funding

Austrian Science Fund FWF T 974
6 · The paper itself

Abstract

Precision oncology approaches for patients with colorectal cancer (CRC) continue to lag behind other solid cancers. Functional precision oncology-a strategy that is based on perturbing primary tumor cells from cancer patients-could provide a road forward to personalize treatment. We extend this paradigm to measuring proteome activity landscapes by acquiring quantitative phosphoproteomic data from patient-derived organoids (PDOs). We show that kinase inhibitors induce inhibitor- and patient-specific off-target effects and pathway crosstalk. Reconstruction of the kinase networks revealed that the signaling rewiring is modestly affected by mutations. We show non-genetic heterogeneity of the PDOs and upregulation of stemness and differentiation genes by kinase inhibitors. Using imaging mass-cytometry-based profiling of the primary tumors, we characterize the tumor microenvironment (TME) and determine spatial heterocellular crosstalk and tumor-immune cell interactions. Collectively, we provide a framework for inferring tumor cell intrinsic signaling and external signaling from the TME to inform precision (immuno-) oncology in CRC.

Indexed as

CancerCancer systems biologyProteomics

Identifiers

PMID38047086
PMCPMC10692669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.